Functional bowel symptoms in quiescent inflammatory bowel diseases: Role of epithelial barrier disruption and low-grade inflammation

Gut

Volumn 63, Issue 5, 2014, Pages 744-752

  Vivinus Nebot M ^a,b   Frin Mathy, G ^a   Bzioueche, H ^b   Dainese, R ^a   Bernard, G ^a,b   Anty, R ^a,c   Filippi, J ^a   Saint Paul, M C ^a   Tulic, M K ^b   Verhasselt, V ^b   Hebuterne X ^a   Piche, Thierry ^a,b  

^a UNIVERSITY HOSPITAL OF NICE   (France)

^b UNIVERSITÉ CÔTE D'AZUR   (France)

^c CENTRE MÉDITERRANÉEN DE MÉDECINE MOLÉCULAIRE C3M   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA CATENIN; MESSENGER RNA; OCCLUDIN; PROTEIN ZO1; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CECUM; CONTROLLED STUDY; CROHN DISEASE; DISEASE SEVERITY; EOSINOPHIL; EPITHELIAL BARRIER DISRUPTION; FEMALE; GASTROINTESTINAL MUCOSA; HUMAN; HUMAN TISSUE; INFLAMMATORY BOWEL DISEASE; IRRITABLE COLON; LYMPHOCYTE; MAJOR CLINICAL STUDY; MALE; MAST CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUALITY OF LIFE; REAL TIME POLYMERASE CHAIN REACTION; SCORING SYSTEM; SUPERNATANT; SYMPTOM; ULCERATIVE COLITIS;

ABDOMINAL PAIN; INFLAMMATORY BOWEL DISEASE; IRRITABLE BOWEL SYNDROME; TIGHT JUNCTION; TNF-ALPHA;

ADULT; AGED; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; COLON; CROHN DISEASE; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTESTINAL MUCOSA; IRRITABLE BOWEL SYNDROME; LEUKOCYTE COUNT; MALE; MIDDLE AGED; PERMEABILITY; PROSPECTIVE STUDIES; REAL-TIME POLYMERASE CHAIN REACTION; SEVERITY OF ILLNESS INDEX; TIGHT JUNCTIONS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84897985897     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2012-304066     Document Type: Article

References (42)

1. Collins SM, Piche T, Rampal P. The putative role of inflammation in the irritable bowel syndrome. Gut 2001;49:743-5. (Pubitemid 33096023)
2. Piche T, Barbara G, Aubert P, et al. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut 2009;58:196-201.
3. Piche T, Ducrotté P, Sabate JM, et al. Impact of functional bowel symptoms on quality of life and fatigue in quiescent Crohn disease and irritable bowel syndrome. Neurogastroenterol Motil 2010;22:626-e174.
4. Halpin SJ, Ford AC. Prevalence of symptoms meeting criteria for irritable bowel syndrome in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol 2012;107:1474-82.
5. Keohane J, O'Mahony C, O'Mahony L, et al. Irritable bowel syndrome-type symptoms in patients with infl ammatory bowel disease: a real association or reflection of occult inflammation? Am J Gastroenterol 2010;105:1788,1789-94.
6. Akbar A, Yiangou Y, Facer P, et al. Expression of the TRPV1 receptor differs in quiescent inflammatory bowel disease with or without abdominal pain. Gut 2010;59:767-74.
7. Salim SY, Söderholm JD. Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflamm Bowel Dis 2011;17:362-81.
8. Gecse K, Róka R, Séra T, et al. Leaky gut in patients with diarrhea-predominant irritable bowel syndrome and inactive ulcerative colitis. Digestion 2012;85:40-6.
9. Zhou Q, Zhang B, Verne GN. Intestinal membrane permeability and hypersensitivity in the irritable bowel syndrome. Pain 2009;146:41-6.
10. Bertiaux-Vandaële N, Youmba SB, Belmonte L, et al. The expression and the cellular distribution of the tight junction proteins are altered in irritable bowel syndrome patients with differences according to the disease subtype. Am J Gastroenterol 2011;106:2165-73.
11. D'Inca R, Di Leo V, Corrao G, et al. Intestinal permeability test as a predictor of clinical course in Crohn's disease. Am J Gastroenterol 1999;94:2956-60. (Pubitemid 29482764)
12. Arnott ID, Kingstone K, Ghosh S. Abnormal intestinal permeability predicts relapse in inactive Crohn disease. Scand J Gastroenterol 2000;35:1163-9.
13. Piche T, Saint-Paul MC, Dainese R, et al. Mast cells and cellularity of the colonic mucosa correlated with fatigue and depression in irritable bowel syndrome. Gut 2008;57:468-73. (Pubitemid 351442529)
14. Barbara G, Stanghellini V, De Giorgio R, et al. Activated mast cells in proximity to colonic nerves correlate with abdominal pain in irritable bowel syndrome. Gastroenterology 2004;126:693-702. (Pubitemid 38298317)
15. Salim SY, Söderholm JD. Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflamm Bowel Dis 2011;17:362-81.
16. Zeissig S, Bojarski C, Buergel N, et al. Downregulation of epithelial apoptosis and barrier repair in active Crohn's disease by tumour necrosis factor alpha antibody treatment. Gut 2004;53:1295-302. (Pubitemid 39120115)
17. Söderholm JD, Streutker C, Yang PC, et al. Increased epithelial uptake of protein antigens in the ileum of Crohn's disease mediated by tumour necrosis factor alpha. Gut 2004;53:1817-24. (Pubitemid 39556903)
18. Heller F, Florian P, Bojarski C, et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 2005;129:550-64. (Pubitemid 41096643)
19. Ma TY, Boivin MA, Ye D, et al. Mechanism of TNF-{alpha} modulation of Caco-2. intestinal epithelial tight junction barrier: role of myosin light-chain kinase protein expression. Am J Physiol Gastrointest Liver Physiol 2005;288:G422-30. (Pubitemid 40261739)
20. Ye D, Ma I, Ma TY. Molecular mechanism of tumor necrosis factor-alpha modulation of intestinal epithelial tight junction barrier. Am J Physiol Gastrointest Liver Physiol 2006;290:G496-504.
21. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987;317:1625-9. (Pubitemid 18010466)
22. Mary JY, Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicentre study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 1989;30:983-9.
23. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006;130:1480-91.
24. Francis CY, Morris J, Whorwell PJ. The irritable bowel severity scoring system: a simple method of monitoring irritable bowel syndrome and its progress. Aliment Pharmacol Ther 1997;11:395-402. (Pubitemid 27183522)
25. Vivinus-Nébot M, Dainese R, Anty R, et al. Combination of allergic factors can worsen diarrheic irritable bowel syndrome: role of barrier defects and mast cells. Am J Gastroenterol 2012;107:75-81.
26. West MA, Koons A. Endotoxin tolerance in sepsis: concentration-dependent augmentation or inhibition of LPS-stimulated macrophage TNF secretion by LPS pretreatment. J Trauma 2008;65:893-8.
27. Bonome T, Lee JY, Park DC, et al. Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary. Cancer Res 2005;65:10602-12. (Pubitemid 41743756)
28. Vivinus-Nebot M, Rousselle P, Breittmayer JP, et al. Mature Human Thymocytes Migrate on Laminin-5 with Activation of Metalloproteinase-14 and Cleavage of CD44. J Immunol 2004;172:1397-406. (Pubitemid 38116781)
29. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)). Method Methods 2001;25:402-8. (Pubitemid 34164012)
30. Wakkach AN, Fournier V, Brun JP, et al. Characterization of dendritic cells that induce tolerance and T regulatory 1 cell differentiation in vivo. Immunity 2003;18:605.
31. Chadwick VS, Chen W, Shu D, et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002;122:1778-83. (Pubitemid 34651421)
32. Salim SY, Söderholm JD. Importance of Disrupted Intestinal Barrier in Inflammatory Bowel Diseases. Inflamm Bowel Dis 2011;17:362-81.
33. Tornblom H, Lindberg G, Nyberg B, et al. Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology 2002;123:1972-9. (Pubitemid 35408321)
34. Barbara G. Mucosal barrier defects in irritable bowel syndrome. Who left the door open? Am J Gastroenterol 2006;101:1295-8. (Pubitemid 43829996)
35. Martínez C, Lobo B, Pigrau M, et al. Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier. Gut 2012;62:1160-8.
36. Balestra B, Vicini R, Cremon C, et al. Colonic mucosal mediators from patients with irritable bowel syndrome excite enteric cholinergic motor neurons. Neurogastroenterol Motil 2012;24:118-e570.
37. Annaházi A, Gecse K, Dabek M, et al. Fecal proteases from diarrheic-IBS and ulcerative colitis patients exert opposite effect on visceral sensitivity in mice. Pain 2009;144:209-17.
38. Mullin JM, Laughlin KV, Marano CW, et al. Modulation of tumor necrosis factor-induced increase in renal (LLC-PK1) transepithelial permeability. Am J Physiol 1992;263:F915-24.
39. Marano CW, Lewis SA, Garulacan LA, et al. Tumor necrosis factor-alpha increases sodium and chloride conductance across the tight junction of CACO-2 BBE, a human intestinal épithelial cell line. J Membr Biol 1998;161:263-74. (Pubitemid 28085051)
40. Suenaert P, Bulteel V, Lemmens L, et al. Anti-tumor necrosis factor treatment restores the gut barrier in Crohn's disease. Am J Gastroenterol 2002;97:2000-4.
41. Bonaz BL, Bernstein CN. Brain-gut interactions in inflammatory bowel disease. Gastroenterology 2013;144:36-49.
42. Azpiroz F, Bouin M, Camilleri M, et al. Mechanisms of hypersensitivity in IBS and functional disorders. Neurogastroenterol Motil 2007;19(1 Suppl):62-88. (Pubitemid 46058983)